Fusion Antibodies Share Discussion Threads

[soultrading] 22/5/2024 12:48

Very little under 3.7 available before next move higher

[gregb] 21/5/2024 09:06

Oops, that should have been on the Lung Life AI group. Very sorry, everyone. Thank you, Trout, for pointing out my mistake. I can't delete the post from my phone but will do as soon as I access my laptop.

[troutisout] 21/5/2024 08:45

You must be on the wrong thread???

[gregb] 21/5/2024 07:42

Deleted Post. Wrong thread, sorry.

[gtc1508] 20/5/2024 10:57

Fusion’s market capitalisation is £3.3m, suggesting an EV of £2.1m, based on year £1.2m end cash. We consider this to represent an interesting special situation geared to the success of Fusion’s recovery plan, where almost no value is currently being ascribed to its class leading antibody discovery technologies. This unusual situation has arisen as a result of the steep decline in revenue Fusion experienced in H2 FY23 that extended into FY24.

Given there is evidence of a turnaround in its fortunes and helped by an improved funding environment for biotech generally and its order book is now on an upward trajectory, our investment thesis is that investors will start to recognise the value inherent in Fusion’s class leading antibody discovery technology. To highlight this, we would draw attention to the valuation of Absci (Nasdaq: ABSI), an albeit much-larger US/Canadian-based firm that has an AI-led approach to antibody drug design. This company has a market capitalisation of $535m and cash of $72m, so has an EV of $463m.

[gtc1508] 16/5/2024 18:12

Investor presentation link

[gtc1508] 15/5/2024 23:28

Another £100k grant funded project there involved inToday 23:26
Another £100k grant funded project there involved in, awarded in April this year:

hxxps://gtr.ukri.org/projects?ref=10106193

The project's primary objective is to establish a local supply chain to produce Titan test kits. Causeway will use subcontractors to carry out critical elements of the kit assembly process. Fusion Antibodies, world experts in antibody production, will manufacture and purify an IgG1 monoclonal antibody, which will be used as the standard in the Titan test kits.

The project aims to generate real-time data by monitoring antibody production and purification processes at Fusion Antibodies. This data will be used to create application notes and technical documentation for Titan, providing valuable insights into its performance and applications.

Causeway Sensors anticipates that Titan will significantly impact biopharmaceutical manufacturing, introducing advanced process analytical testing (PAT) sensors for more efficient and data-informed manufacturing of biotherapeutics. The project reflects our commitment to local collaboration and expertise development in this field, contributing to increased activity in Northern Ireland's growing Life Sciences sector.

[bobaxe1] 15/5/2024 16:36

Investor meet company presentation tomorrow 11am

[bobaxe1] 14/5/2024 22:28

Chart building!//https://x.com/darrenukdaytra1/status/1790328577944109057?s=46&t=KHNNXk1Nw1j5lyzHBSnKag

[soultrading] 13/5/2024 11:07

Slow starting so far. A number of people talked about buying in before presentation so hopefully when one buys the others will jump in to.

[soultrading] 12/5/2024 09:46

Could be a good week ahead.

[soultrading] 10/5/2024 09:37

Be nice to close above 3.5 that would get the technical traders in.

[soultrading] 10/5/2024 09:15

Buyers all of a sudden

[soultrading] 10/5/2024 09:02

100% thinking about adding. Wonder if we will hear more ahead of the presentation, also note the bigger guns are going to bio24 along with the USA Irish investment fund.

[troutisout] 07/5/2024 10:24

Good interview.
Rather than wait until the new traction is proven, those investors looking for maximum reward, must be looking at the current price and thinking about adding...

[bobaxe1] 03/5/2024 10:46

Significant increase in sales pipeline opportunities during H2 FY2024, with an orderbook at 31 March 2024 of £0.75m, representing 65 per cent. of total FY2024 unaudited revenues

[bobaxe1] 01/5/2024 13:55

Great price down here

[jaknife] 30/4/2024 16:35

bobaxe1,

"On the contrary that was a strong update."

Is that why the share price crashed 10% on the day? Because it was a "strong update"?

What in particular did you think was "strong"? Was it the revenue news?

"Unaudited revenues for FY2024 of £1.14m (FY2023: £2.90m)"

^^ Down over 60%!

"Significant increase in sales pipeline opportunities during H2 FY2024, with an orderbook at 31 March 2024 of £0.75m, representing 65 per cent. of total FY2024 unaudited revenues"

^^ A trivial sales pipeline that's less than my local sandwich shop!

"Cash position as at 31 March 2024 of £1.2m (31 March 2023: £0.2m)"

^^ They've already started to burn through the £1.37m of funds that were raised in Feb!

At best we're twelves months away from the next fund raise. At worst your fellow shareholders will finally cotton on that this is a total basket case that's not worth supporting.

JakNife

[bobaxe1] 30/4/2024 13:47

On the contrary that was a strong update. The company has raised well above the current share price at 5.66 . Cash is great going forward had our best month earnings in years delayed earnings will arrive. So just sitting oversold with the usual trolls giving their pennies worth

[jaknife] 30/4/2024 12:59

Yet another poor trading update for this POS company:



It's not true what the adverts say that "past performance is not a guide to future performance", it is 100% the case that "once a dog, always a dog"!

JakNife

[deltalo] 15/4/2024 15:04

Royalties have the potential to bring in much higher revenues, good choice by the company, I expect many more contracts to start feeding through.

[inaminute] 15/4/2024 11:36

What is the upfront value???

[bobaxe1] 15/4/2024 10:56

Great news this morning I have had another top up more to follow